RNA interference and nanomedicine join forces to fight dangerous fungal infections
Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...
Nanowerk12h
Nanomedicine with siRNA shows first effectiveness against the human-pathogenic fungus Aspergillus fumigatus
The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...
Informationsdienst Wissenschaft18h
Major Progress in the Development of New Medications Against Dangerous Fungal Infections
Home > Pressemitteilung: Major Progress in the Development of ...
Pharmabiz1d
Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference
Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...
Seeking Alpha1d
SLXNW Silexion Therapeutics Corp Wt Exp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based ... for the development of an advanced siRNA formulation to enhance cancer treatment.
Nature2d
Stable expression of fluorescently tagged proteins for studies of mitosis in mammalian cells
In practice, when viewing cells with tungsten light for phase contrast or differential interference contrast (DIC) microscopy, using green light and/or adding a heat cut filter is sufficient to ...
Nature6d
Protein–protein interaction networks articles from across Nature Portfolio
Here, authors identify ABHD17B via an siRNA screen and show that ABHD17B regulates the fibrotic activity of HSCs and promotes liver fibrosis in vivo. Here the authors show that lipid exposed ...